SCILEX HOLDING COMPANY - COMMON STOCK

Scilex Holding Company Presented Oral and Poster Presentations on ZTlido (lidocaine topical system) at the 2023 Annual PAINWeek Conference Held in Las Vegas, NV

12 Sep 2023 09:00:00 By Nasdaq GlobeNewswire

Scilex Holding Company Presented Oral and Poster Presentations on Elyxyb at the 2023 Annual Brain Week Conference Held in Las Vegas, NV

12 Sep 2023 09:00:00 By Nasdaq GlobeNewswire

Scilex Holding Company Generates Record Monthly Revenue In August 2023 And Provides Certain Preliminary Unaudited Financial Results For Gross And Net Sales For The One Month Ended August 2023, And Year-To-Date As Of August 31 2023, Based On Currently Available Information

11 Sep 2023 09:00:00 By Nasdaq GlobeNewswire

Scilex Holding Company Announces Results From Independent Market Research Study Conducted with Pain Specialists and HCPs Treating Post-Herpetic Neuralgia (PHN) Pain on ZTlido®

13 Jul 2023 09:00:01 By Nasdaq GlobeNewswire

Scilex Holding Company Generates Record Monthly Revenue In June 2023 And Provides Certain Preliminary Unaudited Financial Results For Gross And Net Sales For The One Month Ended June 2023, Quarter Ended June 2023, And Year-To-Date As Of June 2023, Based On Currently Available Information

05 Jul 2023 09:00:00 By Nasdaq GlobeNewswire

Scilex Holding Company to Present Data on ELYXYB™ (celecoxib oral solution) at the 65th Annual Scientific Meeting of the American Headache Society, in Austin, TX.

16 Jun 2023 09:00:00 By Nasdaq GlobeNewswire

Scilex Holding Company Announces that Sorrento Therapeutics, Inc.’s Bankruptcy Court Issues Temporary Restraining Order Against Brokerage Firms and Suspends Short-Sales of Dividended Scilex Stock

15 Jun 2023 09:03:00 By Nasdaq GlobeNewswire

Scilex Holding Company provides certain preliminary unaudited financial results for gross and net Sales for the one month ended May 2023, and year-to-date May 2023, based on currently available information

01 Jun 2023 12:28:41 By Nasdaq GlobeNewswire

Scilex Holding Company Enters Master Distributor Agreement Among CH Trading Group LLC (“CHT” or “Territories Distributor”) and Farouk, Maamoun Tamer & Co. (“Master Distributor”) For the Distribution of ZTlido® in the Kingdom of Saudi Arabia

31 May 2023 15:16:05 By Nasdaq GlobeNewswire

Scilex Holding Company Added to the Preliminary List of the Russell 3000® Index and the Small-Cap Russell 2000® Index as part of the 2023 Russell Indexes Annual Reconstitution in June 2023

22 May 2023 09:00:00 By Nasdaq GlobeNewswire

Scilex Holding Company Announces Complete Enrollment of a Phase 2 Study to Evaluate the Safety and Efficacy of SP-103 (lidocaine topical system) 5.4%, Triple Strength Formulation of ZTlido®, for the Treatment of Acute Low Back Pain

04 May 2023 09:00:01 By Nasdaq GlobeNewswire

Scilex Holding Company to Participate in the H.C. Wainwright BioConnect Investor Conference at Nasdaq on May 2, 2023

28 Apr 2023 09:00:00 By Nasdaq GlobeNewswire

Scilex Holding Company Announces that its Majority Stockholder, Sorrento Therapeutics, Inc., has Issued a Notice that Sorrento’s Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Stock Distributed by Sorrento to its Stockholders as a Dividend

25 Apr 2023 19:30:00 By Nasdaq GlobeNewswire

Scilex Holding Company Enters into Master Distributor Agreement with CH Trading Group LLC and AD Ports Group for the Distribution of ZTlido® in the Middle East and North Africa Region

17 Apr 2023 09:00:00 By Nasdaq GlobeNewswire

Scilex Holding Company Announces Final Postponement of Annual Meeting of Stockholders

14 Apr 2023 18:32:00 By Nasdaq GlobeNewswire

Scilex Holding Company Announces Postponement of Annual Meeting of Stockholders

05 Apr 2023 17:27:43 By Nasdaq GlobeNewswire

Scilex Holding Company Reports Substantial Underreporting of More Than 44 Million Shares of its Common Stock by Brokerage Firms for the Upcoming Annual Meeting of Stockholders Scheduled for April 6, 2023 and Issues a Supplement to its Previously Issued “FAQ” Regarding the Dividend of Scilex Holding Company Common Stock

27 Mar 2023 09:00:00 By Nasdaq GlobeNewswire

Scilex Holding Company Announces Financing of up to $25 Million to Enhance Commercialization of Three FDA Approved Non-Opioid Pain Management Products

21 Mar 2023 09:00:02 By Nasdaq GlobeNewswire

Scilex Holding Company and CH Trading Group Announce Territory Distribution Agreement to Expand Commercialization of ZTlido® for the Middle East and North Africa (MENA) With $105 Million Minimum Multi-Year Purchase Commitment

08 Mar 2023 10:13:07 By Nasdaq GlobeNewswire

Scilex Holding Company announces the commercial launch of ELYXYBTM (celecoxib oral solution) in the U.S., strengthening its leadership position in non-opioid pain management

27 Feb 2023 09:00:01 By Nasdaq GlobeNewswire